New rules in China are expected to tighten regulatory oversight of investigator-initiated trials (IITs) while clarifying how sponsors can operate legally across modalities beyond cell and gene therapies. The update is aimed at curbing the “gray market” for IIT arrangements by moving more activities under consistent supervision. The regulatory shift follows ongoing scrutiny of trial conduct and data integrity, and it signals that China’s trial ecosystem is being structured to support broader innovation pathways. For biotech companies, the changes may affect clinical strategy, contract structures, and how evidence is generated for new indications. As China continues to expand global influence in drug development, compliance planning for IIT-based studies is likely to become more central for both domestic developers and foreign partners collaborating on trials.